Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.67 |
| ▸ | MMP2 | P08253 | 4/20 | 0.67 |
| ▸ | MMP9 | P14780 | 4/20 | 0.67 |
| ▸ | NAMPT | P43490 | 10/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167756 | 1.00 | MMP1 (0.67) | MMP1MMP2MMP9NAMPTUSP2 | |
| SCHEMBL6168453 | 0.84 | ALDH1A1 (0.60) | MMP1MMP2MMP9NAMPTPOLB | |
| SCHEMBL6168462 | 0.84 | ALDH1A1 (0.60) | MMP1MMP2MMP9NAMPTPOLB | |
| SCHEMBL7994511 | 0.83 | NAMPT (0.53) | MMP1MMP2MMP9NAMPTHDAC3 | |
| SCHEMBL7994516 | 0.83 | NAMPT (0.53) | MMP1MMP2MMP9NAMPTHDAC3 | |
| SCHEMBL6166592 | 0.82 | NAMPT (0.54) | MMP1MMP2MMP9NAMPTHDAC3 | |
| SCHEMBL6166590 | 0.82 | NAMPT (0.54) | MMP1MMP2MMP9NAMPTHDAC3 | |
| SCHEMBL29186139 | 0.81 | MMP1 (0.58) | MMP1MMP2MMP9NAMPTHDAC3 | |
| SCHEMBL30866126 | 0.81 | MMP1 (0.58) | MMP1MMP2MMP9NAMPTHDAC3 | |
| SCHEMBL7991010 | 0.80 | NAMPT (0.51) | MMP1MMP2MMP9NAMPTHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1495757-A1 | PHOSPHODIESTERASE IV INHIBITOR CONTAINING PYRIDYLACRYLAMIDE DERIVATIVE | TSUMURA & CO. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6313153-B1 | ADMINISTERING PYRIDYLACRYLAMIDE COMPOUND FOR THERAPY OF NEPHRITIS | TSUMURA & CO. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1000935-A1 | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-$g(b) INHIBITORS CONTAINING THE SAME | TSUMURA & CO. (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187264-A1 | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | PDE3B, PDE3A, PDE2A | MMP1 61/4885MMP2 82/4885MMP9 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.